All articles tagged with #tau protein
Originally Published 4 months ago — by Earth.com
A new blood test for Alzheimer's disease, measuring tau and amyloid proteins, offers 90% accuracy in early detection, potentially transforming diagnosis and care by providing a faster, less invasive, and more accessible tool especially useful in primary care settings.
Originally Published 5 months ago — by PsyPost
A new study suggests that abnormal glycogen buildup in neurons may contribute to Alzheimer's disease by disrupting energy management and increasing oxidative stress, and that breaking down glycogen could offer a new therapeutic approach.
Originally Published 7 months ago — by futurity.org
A study shows that the sleep medication lemborexant can reduce tau protein buildup and brain damage in mice, suggesting potential for treating or preventing neurodegenerative diseases like Alzheimer's by improving sleep and targeting tau-related pathology.
Originally Published 7 months ago — by Medical News Today
A mouse study suggests that the insomnia drug lemborexant may improve sleep and protect the brain from tau protein buildup, which is linked to Alzheimer's disease, potentially reducing brain damage and inflammation. However, further research in humans is needed to confirm these findings.
Originally Published 7 months ago — by Neuroscience News
A sleep medication called lemborexant may protect the brain from Alzheimer's-related damage by reducing tau buildup and inflammation, with notable effects in male mice, suggesting potential for treating neurodegenerative diseases.
Originally Published 7 months ago — by Medical Xpress
A study shows that the sleep medication lemborexant can prevent tau buildup and brain damage in mice, suggesting potential for treating or preventing neurodegenerative diseases like Alzheimer's by improving sleep and reducing harmful protein accumulation.
Originally Published 1 year ago — by SILive.com
A study published in Nature Neuroscience has identified the enzyme tyrosine kinase 2 (TYK2) as a potential target for treating Alzheimer's disease. In genetically modified mice with excessive tau protein, blocking TYK2 reduced harmful tau buildup and showed signs of neuronal recovery. This discovery could lead to new drug development, although further research is needed to confirm these findings in humans.
Originally Published 1 year ago — by ScienceAlert
A new study suggests that blocking the enzyme tyrosine kinase 2 (TYK2) may help reduce the toxic buildup of tau protein in the brain, a key feature of Alzheimer's disease. Researchers found that TYK2 adds a tag to tau, making it difficult for the brain to clear, leading to neurofibrillary tangles. By inhibiting TYK2 in mice, the study showed a reduction in harmful tau and signs of neuronal recovery, indicating potential for new Alzheimer's treatments. However, further research is needed to confirm these findings in humans.
Originally Published 1 year ago — by PsyPost
Scientists at Weill Cornell Medicine have developed a human neuron model that simulates the spread of tau protein aggregates in the brain, shedding light on potential drug targets to block this process. Using CRISPR/Cas9 technology, the researchers created a neuron model with diseased forms of tau, allowing them to observe tau spread within weeks. Through CRISPRi screening, they identified 500 genes that impact tau abundance, including the UFMylation cascade, which, when altered, could block tau propagation. This finding was validated in both human neurons and mouse models, offering new directions for the development of treatments for Alzheimer’s disease and related conditions.
Originally Published 1 year ago — by Endpoints News
Labcorp has introduced a new blood test to detect the tau protein, which accumulates in the brain after the buildup of amyloid plaques, a hallmark of Alzheimer's disease. This test is now available to doctors and drugmakers, offering a simple way to predict the likelihood of Alzheimer's disease in individuals.
Originally Published 1 year ago — by Medical News Today
A new study published in JAMA Neurology suggests that a blood test screening for Alzheimer's disease may be effective in detecting changes in amyloid beta and tau protein levels in the brain years before symptoms appear. The test, developed by a company called AD-Detect, was found to accurately identify abnormal levels of amyloid beta and tau in 80% of tested participants, potentially allowing for early intervention with emerging pharmaceutical treatments designed to reduce amyloid buildup. However, some experts caution that blood biomarkers may not have a clinical role in evaluating patients with memory loss and dementia, and using them for diagnosis could lead to overdiagnosis and unnecessary treatment.
Originally Published 2 years ago — by Medical Xpress
A woman from a Colombian family with a history of early-onset Alzheimer's disease managed to evade the disease despite carrying the genetic defect. Researchers have discovered that she carried a rare variant of the APOE gene known as the Christchurch mutation, which severed the link between the early phase of Alzheimer's (amyloid beta buildup) and the late phase (tau protein accumulation). This finding suggests a new approach to preventing Alzheimer's dementia by mimicking the effects of the APOE Christchurch mutation to halt the progression of the disease.
Originally Published 2 years ago — by Neuroscience News
Researchers have identified a gene allele, known as DR4, that offers more than a 10% average reduction in the risk of Alzheimer’s and Parkinson’s diseases. The study suggests a potential role of the tau protein in both conditions. The DR4 allele prompts the immune system to target a specific segment of tau, potentially disrupting the formation of harmful brain aggregates. This discovery opens doors for targeted vaccines that could slow or even halt the progression of these neurodegenerative diseases.
Originally Published 2 years ago — by Medical Xpress
A new study has found that about one in five people carries a genetic variant, known as DR4, that provides protection against both Alzheimer's disease and Parkinson's disease. The study suggests that this protective allele may be involved in immune responses that limit the accumulation of misfolded tau protein, a hallmark of both diseases. The researchers propose that a vaccine targeting acetylated PHF6, a modified segment of tau, could potentially delay or slow the progression of Alzheimer's and Parkinson's in individuals carrying the DR4 variant. However, further research is needed to determine the effectiveness of such a vaccine.
Originally Published 2 years ago — by New York Post
Compounds found in espresso, including caffeine, have been found to potentially prevent the development of Alzheimer's disease, according to a study conducted at the University of Verona in Italy. The compounds were shown to inhibit the formation of tau protein fibrils associated with Alzheimer's disease, which disrupt the communication between nerve cells in the brain. While more research is needed, this discovery could lead to the development of bioactive compounds for the treatment of neurological diseases like Alzheimer's. Additionally, recent advancements in drug therapies, such as donanemab, have shown promise in slowing the progression of Alzheimer's disease.